ATXN3 and Ataxia: A dose-dependent effect of daily CoQ10 on decreasing scale for the assessment and rating of ataxia (SARA) scores was demonstrated in SCA3 patients [25], suggesting the importance of clarifying regulatory mechanisms of SCA3 pathology susceptible to CoQ10 treatment.